First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent

Catheter Cardiovasc Interv. 2007 Jan;69(1):128-31. doi: 10.1002/ccd.20895.

Abstract

The first-in-human fully bioabsorbable drug-eluting stent (BVS poly-L-lactic acid everolimus-eluting coronary stent) implantation was performed at Auckland City Hospital, New Zealand as part of the ABSORB trial. There were no adverse events in-hospital or by 1 month. A stent that supports the vessel when needed, delivers an antiproliferative drug then disappears has theoretical advantages with regard to CT and MRI compatibility, restored vessel vasomotion, and facilitated future percutaneous intervention or surgical grafting to the treated site.

Publication types

  • Case Reports

MeSH terms

  • Absorbable Implants
  • Angina Pectoris / therapy*
  • Coronary Angiography
  • Drug Delivery Systems
  • Everolimus
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Lactic Acid
  • Male
  • Middle Aged
  • Polyesters
  • Polymers
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives*
  • Stents*
  • Ultrasonography, Interventional

Substances

  • Immunosuppressive Agents
  • Polyesters
  • Polymers
  • Lactic Acid
  • poly(lactide)
  • Everolimus
  • Sirolimus